Impact of genomic testing on urologists' treatment preference in favorable risk prostate cancer: A randomized trial
Abstract
The Oncotype Dx Genomic Prostate Score (GPS) is a 17‐gene relative expression assay that predicts adverse pathology at prostatectomy. We conducted a novel randomized controlled trial to assess the impact of GPS on urologist's treatment preference for favorable risk prostate cancer (PCa): active surveillance versus active treatment (i.e., prostatectomy/radiation). This is a secondary endpoint from the ENACT trial which recruited from three Chicago hospitals from 2016 to 2019.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 01, 2023
- Source ID
- 10.1002/cam4.6615
Entities
People
- Adam B Murphy
- Andre Kajdacsy‐balla
- Carol E. Ferrans
- Cordero Mccall
- Courtney M.P. Hollowell
- Daniel Moreira
- Heidy Wang
- Karen Ferrer
- Li Ping
- Lisa K. Sharp
- Marin Sekosan
- Marlene Gallegos
- Michael Abern
- Norma Marshall
- Patricia Vidal
- Peter H Gann
- Roohollah Sharifi
- Samuel Carbunaru
- Shoujin Wu
- Zequn Sun
Organizations
- Duke University
- Jesse Brown VA Medical Center
- John H. Stroger, Jr. Hospital of Cook County
- Medical College of Wisconsin
- Northwestern University
- United States Department of Defense
- University of Illinois at Chicago